Regulation of mutant p53 protein expression

Frontiers in Oncology

Volumn 5, Issue DEC, 2015, Pages

  Vijayakumaran, Reshma ^a   Tan, Kah Hin ^a   Miranda, Panimaya Jeffreena ^a   Haupt, Sue ^a   Haupt, Ygal ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Cancer; Mdm2; MiRNA; Mutant p53; Proteasomal degradation

Indexed keywords

AQUAPORIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 1; MEMBRANE PROTEIN; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 16 1; MICRORNA 205; MICRORNA 29; MICRORNA 32; MICRORNA 449; MICRORNA 542 3P; NADH QUINONE OXIDOREDUCTASE 1; PROTEIN CDC42; PROTEIN MDMX; PROTEIN P53; SIRTUIN 1; UNCLASSIFIED DRUG;

CANCER CELL; CHRONIC STRESS; DNA DAMAGE; GENE MUTATION; HUMAN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; REGULATORY MECHANISM; SHORT SURVEY; UBIQUITINATION;

EID: 84954487060     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00284     Document Type: Short Survey

References (96)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature (2000) 408(6810):307-10. doi: 10.1038/35042675.
2. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 28(6):622-9. doi:10.1002/humu.20495.
3. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev (2012) 26(12):1268-86. doi:10.1101/gad.190678.112.
4. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 25(3):304-17. doi:10.1016/j.ccr.2014.01.021.
5. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 119(6):861-72. doi:10.1016/j.cell.2004.11.006.
6. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 63(20):6643-50.
7. Terzian T, Suh Y-A, Iwakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 22(10):1337-44. doi:10.1101/gad.1662908.
8. Hock AK, Vousden KH. The role of ubiquitin modification in the regulation of p53. Biochim Biophys Acta (2014) 1843(1):137-49. doi:10.1016/j.bbamcr.2013.05.022.
9. Saldana-Meyer R, Recillas-Targa F. Transcriptional and epigenetic regulation of the p53 tumor suppressor gene. Epigenetics (2011) 6(9):1068-77. doi:10.4161/epi.6.9.16683.
10. Ellwanger DC, Buttner FA, Mewes HW, Stumpflen V. The sufficient minimal set of miRNA seed types. Bioinformatics (2011) 27(10):1346-50. doi:10.1093/bioinformatics/btr149.
11. Xie C, Chen W, Zhang M, Cai Q, Xu W, Li X, et al. MDM4 regulation by the let-7 miRNA family in the DNA damage response of glioma cells. FEBS Lett (2015) 589(15):1958-65. doi:10.1016/j.febslet.2015.05.030.
12. Huang Y, Chuang AY, Ratovitski EA. Phospho-DeltaNp63alpha/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure. Cell Cycle (2011) 10(22):3938-47. doi:10.4161/cc.10.22.18107.
13. Mandke P, Wyatt N, Fraser J, Bates B, Berberich SJ, Markey MP. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS One (2012) 7(8):e42034. doi:10.1371/journal.pone.0042034.
14. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev (2009) 23(7):862-76. doi:10.1101/gad.1767609.
15. Hoffman Y, Pilpel Y, Oren M. microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network. J Mol Cell Biol (2014) 6(3):192-7. doi:10.1093/jmcb/mju020.
16. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J (1996) 15(19):5349-57.
17. Shvarts A, Bazuine M, Dekker P, Ramos YF, Steegenga WT, Merckx G, et al. Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics (1997) 43(1):34-42. doi:10.1006/geno.1997.4775.
18. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol (2009) 16(1):23-9. doi:10.1038/nsmb.1533.
19. Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, Krogh A, Bardram L, Hother C, et al. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer (2011) 10:29. doi:10.1186/1476-4598-10-29.
20. Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci U S A (2012) 109(14):5316-21. doi:10.1073/pnas.1202465109.
21. Wang Y, Huang JW, Castella M, Huntsman DG, Taniguchi T. p53 is positively regulated by miR-542-3p. Cancer Res (2014) 74(12):3218-27. doi:10.1158/0008-5472.CAN-13-1706.
22. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature (2009) 460(7254):529-33. doi:10.1038/nature08199.
23. Muller PA, Trinidad AG, Caswell PT, Norman JC, Vousden KH. Mutant p53 regulates dicer through p63-dependent and-independent mechanisms to promote an invasive phenotype. J Biol Chem (2014) 289(1):122-32. doi:10.1074/jbc. M113.502138.
24. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H, et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene (2013) 32(27):3286-95. doi:10.1038/onc.2012.334.
25. Wang W, Cheng B, Miao L, Mei Y, Wu M. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death Dis (2013) 4:e574. doi:10.1038/cddis.2013.97.
26. Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, et al. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene (2014) 33(12):1601-8. doi:10.1038/onc.2013.106.
27. Subramanian M, Francis P, Bilke S, Li XL, Hara T, Lu X, et al. A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis. Oncogene (2015) 34(9):1094-104. doi:10.1038/onc.2014.46.
28. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A (2012) 109(38):15312-7. doi:10.1073/pnas.1110977109.
29. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ (2012) 19(6):1038-48. doi:10.1038/cdd.2011.190.
30. Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene (2013) 32(24):2992-3000. doi:10.1038/onc.2012.305.
31. Meek DW, Anderson CW. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol (2009) 1(6):a000950. doi:10.1101/cshperspect.a000950.
32. Kruse JP, Gu W. Modes of p53 regulation. Cell (2009) 137(4):609-22. doi:10.1016/j.cell.2009.04.050.
33. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem (1998) 67:425-79. doi:10.1146/annurev.biochem.67.1.425.
34. MacPherson D, Kim J, Kim T, Rhee BK, Van Oostrom CT, DiTullio RA, et al. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J (2004) 23(18):3689-99. doi:10.1038/sj.emboj.7600363.
35. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature (1997) 387(6630):296-9. doi:10.1038/387296a0.
36. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature (1997) 387(6630):299-303. doi:10.1038/387299a0.
37. Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 15(10):1179-89. doi:10.1038/sj.onc.1201459.
38. Shimizu H, Burch LR, Smith AJ, Dornan D, Wallace M, Ball KL, et al. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem (2002) 277(32):28446-58. doi:10.1074/jbc. M202296200.
39. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell (2006) 23(2):251-63. doi:10.1016/j.molcel.2006.05.029.
40. Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol (2007) 27(23):8284-95. doi:10.1128/MCB.00050-07.
41. Brignone C, Bradley KE, Kisselev AF, Grossman SR. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway. Oncogene (2004) 23(23):4121-9. doi:10.1038/sj.onc.1207540.
42. Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, PandolfiPP, et al. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle (2013) 12(11):1722-31. doi:10.4161/cc.24805.
43. Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A, et al. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle (2008) 7(19):3056-61. doi:10.4161/cc.7.19.6751.
44. Tasdemir E, Chiara Maiuri M, Morselli E, Criollo A, D'Amelio M, Djavaheri-Mergny M, et al. A dual role of p53 in the control of autophagy. Autophagy (2008) 4(6):810-4. doi:10.4161/auto.6486.
45. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol (2010) 22(2):124-31. doi:10.1016/j.ceb.2009.11.014.
46. Vakifahmetoglu-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofengeim D, ColoffJL, et al. Chaperone-mediated autophagy degrades mutant p53. Genes Dev (2013) 27(15):1718-30. doi:10.1101/gad.220897.113.
47. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev (2002) 82(2):373-428. doi:10.1152/physrev.00027.2001.
48. Pratt WB, Morishima Y, Peng HM, Osawa Y. Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp Biol Med (Maywood) (2010) 235(3):278-89. doi:10.1258/ebm.2009.009250.
49. Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res (2011) 9(5):577-88. doi:10.1158/1541-7786.MCR-10-0534.
50. Wiech M, Olszewski MB, Tracz-Gaszewska Z, Wawrzynow B, Zylicz M, Zylicz A. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS One (2012) 7(12):e51426. doi:10.1371/journal.pone.0051426.
51. Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A (1996) 93(16):8379-83. doi:10.1073/pnas.93.16.8379.
52. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol (1998) 18(3):1517-24. doi:10.1128/MCB.18.3.1517.
53. Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene (2008) 27(24):3371-83. doi:10.1038/sj.onc.1211010.
54. Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ (2011) 18(12):1904-13. doi:10.1038/cdd.2011.71.
55. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell (2005) 18(5):601-7. doi:10.1016/j.molcel.2005.04.021.
56. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci (2006) 31(3):164-72. doi:10.1016/j.tibs.2006.01.006.
57. Xiao X, Zuo X, Davis AA, McMillan DR, Curry BB, Richardson JA, et al. HSF1 is required for extra-embryonic development, postnatal growth and protection during inflammatory responses in mice. EMBO J (1999) 18(21):5943-52. doi:10.1093/emboj/18.21.5943.
58. Li D, Yallowitz A, Ozog L, Marchenko N. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress. Cell Death Dis (2014) 5:e1194. doi:10.1038/cddis.2014.158.
59. Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature (2015) 523(7560):352-6. doi:10.1038/nature14430.
60. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 112(6):779-91. doi:10.1016/S0092-8674(03)00193-4.
61. Sheng Y, Laister RC, Lemak A, Wu B, Tai E, Duan S, et al. Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat Struct Mol Biol (2008) 15(12):1334-42. doi:10.1038/nsmb.1521.
62. Yan W, Jung YS, Zhang Y, Chen X. Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase. PLoS One (2014) 9(8):e103497. doi:10.1371/journal.pone.0103497.
63. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell (2010) 140(3):384-96. doi:10.1016/j.cell.2009.12.032.
64. Dar A, Shibata E, Dutta A. Deubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway. Mol Cell Biol (2013) 33(16):3309-20. doi:10.1128/MCB.00358-13.
65. Masuya D, Huang C, Liu D, Nakashima T, Yokomise H, Ueno M, et al. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J Pathol (2006) 208(5):724-32. doi:10.1002/path.1931.
66. Mori S, Ito G, Usami N, Yoshioka H, Ueda Y, Kodama Y, et al. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer (2004) 100(8):1673-82. doi:10.1002/cncr.20164.
67. Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis (2013) 4:e867. doi:10.1038/cddis.2013.400.
68. Zhang J, Cao M, Dong J, Li C, Xu W, Zhan Y, et al. ABRO1 suppresses tumourigenesis and regulates the DNA damage response by stabilizing p53. Nat Commun (2014) 5:5059. doi:10.1038/ncomms6059.
69. Xiang T, Li L, Yin X, Yuan C, Tan C, Su X, et al. The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS One (2012) 7(1):e29783. doi:10.1371/journal.pone.0029783.
70. Liu J, Chung HJ, Vogt M, Jin Y, Malide D, He L, et al. JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J (2011) 30(5):846-58. doi:10.1038/emboj.2011.11.
71. Tsvetkov P, Reuven N, Shaul Y. Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ (2010) 17(1):103-8. doi:10.1038/cdd.2009.67.
72. Belinsky M, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev (1993) 12(2):103-17. doi:10.1007/BF00689804.
73. Zhou X, Liao WJ, Liao JM, Liao P, Lu H. Ribosomal proteins: functions beyond the ribosome. J Mol Cell Biol (2015) 7(2):92-104. doi:10.1093/jmcb/mjv014.
74. Xiong X, Zhao Y, He H, Sun Y. Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator. Oncogene (2011) 30(15):1798-811. doi:10.1038/onc.2010.569.
75. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell (2005) 123(1):49-63. doi:10.1016/j.cell.2005.07.034.
76. Zhang Y, Wang J, Yuan Y, Zhang W, Guan W, Wu Z, et al. Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26. Nucleic Acids Res (2010) 38(19):6544-54. doi:10.1093/nar/gkq536.
77. Alsheich-Bartok O, Haupt S, Alkalay-Snir I, Saito S, Appella E, Haupt Y. PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene (2008) 27(26):3653-61. doi:10.1038/sj.onc.1211036.
78. Unger T, Juven-Gershon T, Moallem E, Berger M, Sionov RV, Lozano G. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 18(7):1805-14. doi:10.1093/emboj/18.7.1805.
79. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A (1999) 96(24):13777-82. doi:10.1073/pnas.96.24.13777.
80. Melnikova VO, Santamaria AB, Bolshakov SV, Ananthaswamy HN. Mutant p53 is constitutively phosphorylated at serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase. Oncogene (2003) 22(38):5958-66. doi:10.1038/sj.onc.1206595.
81. Yi YW, Kang HJ, Kim HJ, Kong Y, Brown ML, Bae I. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget (2013) 4(7):984-94. doi:10.18632/oncotarget.1070.
82. Zhang ZY, Hong D, Nam SH, Kim JM, Paik YH, Joh JW, et al. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma. J Hepatol (2015) 62(1):121-30. doi:10.1016/j.jhep.2014.08.007.
83. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A (1999) 96(26):14973-7. doi:10.1073/pnas.96.26.14973.
84. Goldberg Z, Sionov RV, Berger M, Zwang Y, Perets R, Van Etten RA, et al. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J (2002) 21(14):3715-27. doi:10.1093/emboj/cdf384.
85. Cheng Q, Chen L, Li Z, Lane WS, Chen J. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J (2009) 28(24):3857-67. doi:10.1038/emboj.2009.294.
86. Pereg Y, Shkedy D, de Graaf P, Meulmeester E, Edelson-Averbukh M, Salek M, et al. Phosphorylation of Hdmx mediates its Hdm2-and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci U S A (2005) 102(14):5056-61. doi:10.1073/pnas.0408595102.
87. Zuckerman V, Lenos K, Popowicz GM, Silberman I, Grossman T, Marine J-C, et al. c-Abl phosphorylates Hdmx and regulates its interaction with p53. J Biol Chem (2009) 284(6):4031-9. doi:10.1074/jbc. M809211200.
88. Deng Q, Becker L, Ma X, Zhong X, Young K, Ramos K, et al. The dichotomy of p53 regulation by noncoding RNAs. J Mol Cell Biol (2014) 6(3):198-205. doi:10.1093/jmcb/mju017.
89. Zhang S, Zhang C, Li Y, Wang P, Yue Z, Xie S. miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. Biomed Pharmacother (2011) 65(6):436-42. doi:10.1016/j.biopha.2011.04.010.
90. Fan Y, Yin S, Hao Y, Yang J, Zhang H, Sun C, et al. miR-19b promotes tumor growth and metastasis via targeting TP53. RNA (2014) 20(6):765-72. doi:10.1261/rna.043026.113.
91. Tay Y, Tan SM, Karreth FA, Lieberman J, PandolfiPP. Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus. Cell Rep (2014) 8(3):714-22. doi:10.1016/j.celrep.2014.06.064.
92. Zhang C, Liu J, Wang X, Wu R, Lin M, Laddha SV, et al. MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. Oncotarget (2014) 5(19):9106-17. doi:10.18632/oncotarget.2379.
93. Jansson MD, Damas ND, Lees M, Jacobsen A, Lund AH. miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2. Oncogene (2015) 34(15):1908-18. doi:10.1038/onc.2014.130.
94. Fortunato O, Boeri M, Moro M, Verri C, Mensah M, Conte D, et al. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. Cell Death Dis (2014) 5:e1564. doi:10.1038/cddis.2014.507.
95. Ren ZJ, Nong XY, Lv YR, Sun HH, An PP, Wang F, et al. Mir-509-5p joins the Mdm2/p53 feedback loop and regulates cancer cell growth. Cell Death Dis (2014) 5:e1387. doi:10.1038/cddis.2014.327.
96. Stegeman S, Moya L, Selth LA, Spurdle AB, Clements JA, Batra J. A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer. Endocr Relat Cancer (2015) 22(2):265-76. doi:10.1530/ERC-15-0013.